Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters
- PMID: 28646995
- DOI: 10.1016/j.kint.2017.04.006
Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters
Erratum in
-
Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int. 2017;92:26-36.Kidney Int. 2017 Dec;92(6):1558. doi: 10.1016/j.kint.2017.10.001. Kidney Int. 2017. PMID: 29153145 No abstract available.
Abstract
The KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD represents a selective update of the prior CKD-MBD Guideline published in 2009. This update, along with the 2009 publication, is intended to assist the practitioner caring for adults and children with chronic kidney disease (CKD), those on chronic dialysis therapy, or individuals with a kidney transplant. This review highlights key aspects of the 2017 CKD-MBD Guideline Update, with an emphasis on the rationale for the changes made to the original guideline document. Topic areas encompassing updated recommendations include diagnosis of bone abnormalities in CKD-mineral and bone disorder (MBD), treatment of CKD-MBD by targeting phosphate lowering and calcium maintenance, treatment of abnormalities in parathyroid hormone in CKD-MBD, treatment of bone abnormalities by antiresorptives and other osteoporosis therapies, and evaluation and treatment of kidney transplant bone disease.
Keywords: KDIGO CKD-MBD Guideline; bone mineral density; calcium; dialysis; hyperparathyroidism; hyperphosphatemia; kidney transplantation.
Copyright © 2017 KDIGO. Published by Elsevier Inc. All rights reserved.
Similar articles
-
KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).Am J Kidney Dis. 2017 Dec;70(6):737-751. doi: 10.1053/j.ajkd.2017.07.019. Epub 2017 Sep 21. Am J Kidney Dis. 2017. PMID: 28941764
-
Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.J Nephrol. 2016 Feb;29(1):71-8. doi: 10.1007/s40620-015-0202-4. Epub 2015 May 19. J Nephrol. 2016. PMID: 25986389
-
Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Kidney Int. 2025 Mar;107(3):405-423. doi: 10.1016/j.kint.2024.11.013. Epub 2025 Jan 24. Kidney Int. 2025. PMID: 39864017
-
Osteoporosis and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Back to Basics.Am J Kidney Dis. 2021 Oct;78(4):582-589. doi: 10.1053/j.ajkd.2020.12.024. Epub 2021 Mar 25. Am J Kidney Dis. 2021. PMID: 33774081 Review.
-
Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.Pediatr Nephrol. 2013 Apr;28(4):617-25. doi: 10.1007/s00467-012-2381-8. Epub 2013 Feb 5. Pediatr Nephrol. 2013. PMID: 23381010 Free PMC article. Review.
Cited by
-
Vitamin D Effects on Bone Homeostasis and Cardiovascular System in Patients with Chronic Kidney Disease and Renal Transplant Recipients.Nutrients. 2021 Apr 25;13(5):1453. doi: 10.3390/nu13051453. Nutrients. 2021. PMID: 33922902 Free PMC article. Review.
-
Paget disease of bone in an elderly patient with chronic renal disease and weight loss: A case report.Medicine (Baltimore). 2019 Oct;98(42):e17458. doi: 10.1097/MD.0000000000017458. Medicine (Baltimore). 2019. PMID: 31626101 Free PMC article.
-
An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis.Pediatr Nephrol. 2019 Jan;34(1):145-154. doi: 10.1007/s00467-018-4054-8. Epub 2018 Aug 23. Pediatr Nephrol. 2019. PMID: 30141180 Free PMC article. Clinical Trial.
-
Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study.Int Urol Nephrol. 2023 Jul;55(7):1865-1873. doi: 10.1007/s11255-023-03505-4. Epub 2023 Feb 15. Int Urol Nephrol. 2023. PMID: 36790677
-
Effects of intradialytic aerobic exercise on hemodialysis patients: a systematic review and meta-analysis.J Nephrol. 2019 Aug;32(4):549-566. doi: 10.1007/s40620-018-00565-z. Epub 2019 Jan 18. J Nephrol. 2019. PMID: 30659520 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical